Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 7/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | SUZ12 | Q15022 | 4/20 | 0.35 |
| ▸ | EZH2 | Q15910 | 4/20 | 0.35 |
| ▸ | FADS1 | O60427 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29181184 | 0.88 | MTNR1A (0.41) | EEDMTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL9911358 | 0.80 | GABRA1 (0.48) | EEDMTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL506855 | 0.79 | EED (0.46) | EEDMTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL27940164 | 0.79 | EED (0.46) | EEDMTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL3794946 | 0.79 | MTNR1A (0.51) | EEDMTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL2095736 | 0.79 | EED (0.46) | EEDMTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL5357479 | 0.79 | MAOB (0.47) | EEDMTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL27921496 | 0.79 | EED (0.46) | EEDMTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL5987863 | 0.77 | HTR2A (0.44) | EEDMTNR1AMTNR1BMAOASLC6A2 | |
| SCHEMBL30401257 | 0.77 | HTR2A (0.44) | EEDMTNR1AMTNR1BMAOASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114195811-B | Synthesis of difunctional fluorescent probe and application of difunctional fluorescent probe in simultaneous distinguishing detection of hydrogen peroxide and HClO | 湖南师范大学 | 2023-07-04 | — | — | CN | claimed |
| CN-121914150-A | Preparation method and application of hydrogen peroxide response type organic fluorescent probe | 湖北科技学院 | 2026-04-24 | — | — | CN | disclosed |
| US-12351582-B2 | Aurora kinase inhibitors and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2025-07-08 | — | — | US | disclosed |
| EP-4001276-B1 | AURORA KINASE INHIBITOR AND USE THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2025-06-25 | — | — | EP | disclosed |
| CN-117756829-A | Simultaneous detection H 2 O 2 Fluorescent probe for NADH and preparation method thereof | 南通大学附属医院 | 2024-03-26 | — | — | CN | disclosed |
| CN-108137542-B | Pyridone dicarboxamides as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-114072400-B | Aurora kinase inhibitor and use thereof | 微境生物医药科技(上海)有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-4001276-A1 | AURORA KINASE INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2022-05-25 | — | — | EP | disclosed |
| EP-4001276-A1 | AURORA KINASE INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2022-05-25 | — | — | EP | disclosed |
| CN-114072400-A | Aurora kinase inhibitor and use thereof | 微境生物医药科技(上海)有限公司 | 2022-02-18 | — | — | CN | disclosed |
| WO-2017037116-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017037116-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-09 | — | — | WO | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | EED 3625/4885MTNR1A 3567/4885MTNR1B 3594/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | EED 2810/4885MTNR1A 5/4885MTNR1B 3/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | EED 3481/4885MTNR1A 3105/4885MTNR1B 2963/4885 |
| US-12351582-B2 | Aurora kinase inhibitors and uses thereof | AURKA, AURKC, AURKB | EED 3224/4885MTNR1A 3651/4885MTNR1B 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.